Evidence map›Paper›PMID 39940745›Full record

ArticleInternational journal of molecular sciences2025

Natural Killer Cells in Graves' Disease: Increased Frequency but Impaired Degranulation Ability Compared to Healthy Controls.

Daniela Gallo, Eliana Piantanida, Raffaella Bombelli, Silvia Lepanto, Antonino Bruno, Matteo Gallazzi, Giorgia Bilato, Marina Borgese, Denisa Baci, Lorenzo Mortara and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniela GalloEndocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST Dei Sette Laghi, 21100 Varese, Italy.ORCID 0000-0002-1873-3048
Eliana PiantanidaEndocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST Dei Sette Laghi, 21100 Varese, Italy.ORCID 0000-0002-2360-1621
Raffaella BombelliImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Silvia LepantoEndocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST Dei Sette Laghi, 21100 Varese, Italy.
Antonino BrunoImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.ORCID 0000-0002-4790-0861
Matteo GallazziLaboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry, and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico MultiMedica, 20138 Milan, Italy.
Giorgia BilatoImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Marina BorgeseDepartment of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.ORCID 0009-0005-0723-6424
Denisa BaciImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Lorenzo MortaraImmunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.ORCID 0000-0002-4757-7101
Maria Laura TandaEndocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST Dei Sette Laghi, 21100 Varese, Italy.ORCID 0000-0001-7551-1751

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graves' disease (GD) is an autoimmune disorder, driven by the appearance of circulating autoantibodies (Ab) against the thyroid stimulating hormone (TSH) receptor, thus causing hyperthyroidism. While antithyroid drugs, the only available treatment for GD, carry a significant risk of relapse, advances in immunology could pave the way for more effective therapies. Natural killer (NK) cells, divided into cytotoxic CD56

Indexed as

Cell DegranulationGraves DiseaseKiller Cells, NaturalAdultAgedCase-Control StudiesCytokinesFemaleHumansMaleMiddle AgedYoung AdultCytokinesflow cytometryGraves’ diseaseinnate immunitynatural killer cellspathogenesis

Identifiers

PMID39940745
PMCPMC11816991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.